- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02064062
Autologous Stem Cells in Achilles Tendinopathy (ASCAT)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Tendon disorders compromise pain free activity and often progress to chronic pain with a major impact on quality of life. More than 85,000 patients each year see their general practitioner (GP) with Achilles Tendinopathy (AT) which affects the lower leg in young and middle aged adults. The main treatment is physiotherapy, although surgery is eventually considered in 25-45%of patients, an intervention that requires several months of immobilisation and has unpredictable outcomes.
Other treatments include, shockwave therapy, Platelet Rich Plasma (PRP) (a blood injection of platelet rich plasma) and steroid injections, but other than physiotherapy non have been shown to be better than placebo. There is a need for improved nonsurgical treatments. There is an established treatment in horses that involves injection of the horses own stem cells into the tendon, which has been shown to be effective but has never been used in man. We wish to translate the technology to humans and propose a pilot phase II trial to establish the safety of stem cells implanted in diseased human tendon. We aim to study 10 patients with chronic mid substance achilles tendinopathy to assess safety as our primary outcome measure. In addition we capture clinical outcomes scores and ultrasound appearances. Other than the stem cell injection, all assessments will be non invasive. Participants will be otherwise healthy adults, aged 18-70 and recruited from routine outpatient clinics at the Royal National Orthopaedic Hospital, presenting with a painful heel, diagnosed by a specialist as Achilles tendinopathy, and having already undergone a minimum of 6 months of physiotherapy. Each participant will have 6 months follow up. This study will help inform a larger clinical trial in the future for which a further ethics application will be made.
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Andy Goldberg
- Phone Number: 0208 909 5825
- Email: andy.goldberg@rnoh.nhs.uk
Study Locations
-
-
-
London, United Kingdom, HA74LP
- Recruiting
- Royal National Orthopaedic Hospital
-
Principal Investigator:
- Andrew Goldberg
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Aged ≥18 and ≤ 70 (both males and females)
- Participants with chronic midportion AT (as defined by pain in region of AT and tender swelling in mid portion of AT (no tenderness over bony attachment to heel) with symptoms for longer than 6 months who have failed conservative treatment (at least a full course of physiotherapy) and for whom surgery is being considered
- Able to provide written informed consent
Exclusion Criteria:
- Previous bony surgery (e.g. reconstructive pelvic osteotomy) at or in proximity to the bone marrow harvest site
- Pregnancy or lactation
- Current use of steroids, anti-tumour necrosis factor (TNF) drugs, methotrexate, or ciprofloxacin (or use within 4 weeks of assessment for eligibility)
- Positive for hepatitis B virus (HBV), Hepatitis C virus (HCV), Human Immunodeficiency Virus (HIV 1 and 2), syphilis and human t-cell leukaemia virus (HTLV)
- Previous AT surgery on the tendon to receive mesenchymal stem cell (MSC) implantation
- Inflammatory arthritis
- Known or suspected underlying haematological malignancy
- Other active malignancy in the past 3 years
- Bovine or antibiotic allergy
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Autologous Mesenchymal Stem Cells
|
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The primary safety outcome will be the incidence rate of Serious Adverse Reaction (SAR).
Time Frame: 6 months
|
The primary safety outcome is the incidence rate of SARs.
This will be expressed as the proportion of participants experiencing a SAR at any time over the 24 week follow-up period.
Primary outcomes will be assessed by adverse events reporting, clinical assessment and ultrasound.
|
6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of success
Time Frame: 6 months
|
The secondary efficacy outcome measure is the incidence of success at 6 months, where success is defined as a reduction of 2 or more points on VAS of pain and an increase of VISA-A score greater than the Minimum Clinically Important Difference (MCID).
|
6 months
|
Conventional ultrasound changes from baseline
Time Frame: Baseline immediately before implantation and at weeks 6, 12 and 24
|
Baseline immediately before implantation and at weeks 6, 12 and 24
|
|
Ultrasound Tissue Characterisation (UTC) changes from baseline
Time Frame: Baseline immediately before implantation and at weeks 6, 12 and 24
|
Baseline immediately before implantation and at weeks 6, 12 and 24
|
|
Inter-observer reliability of UTC against conventional US
Time Frame: Baseline immediately before implantation and at weeks 6, 12 and 24
|
Baseline immediately before implantation and at weeks 6, 12 and 24
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Andrew Goldberg, MBBS MD FRCSI FRCS(Tr&Orth), Royal National Orthopaedic Hospital NHS Trust, UCL
Publications and helpful links
General Publications
- Smith RK, Korda M, Blunn GW, Goodship AE. Isolation and implantation of autologous equine mesenchymal stem cells from bone marrow into the superficial digital flexor tendon as a potential novel treatment. Equine Vet J. 2003 Jan;35(1):99-102. doi: 10.2746/042516403775467388. No abstract available.
- Goldberg AJ, Zaidi R, Brooking D, Kim L, Korda M, Masci L, Green R, O'Donnell P, Smith R. Autologous Stem Cells in Achilles Tendinopathy (ASCAT): protocol for a phase IIA, single-centre, proof-of-concept study. BMJ Open. 2018 May 14;8(5):e021600. doi: 10.1136/bmjopen-2018-021600.
Helpful Links
Study record dates
Study Major Dates
Study Start
Primary Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 12/0419
- 2013-000966-12 (EUDRACT_NUMBER)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Tendinopathy
-
University of CadizNot yet recruitingTendinopathy | Achilles Tendinopathy | Tendinopathy, Elbow | Patellar Tendinopathy | Tendinopathy Rotator CuffSpain
-
University of CalgarySport Science Association of Alberta (SSAA)UnknownAchilles Tendinopathy | Achilles Tendon Enthesopathy | Mid-Portion Achilles Tendinopathy | Insertional Achilles Tendinopathy | Non-Insertional Achilles TendinopathyCanada
-
Krankenhaus Barmherzige Schwestern LinzActive, not recruitingAchilles Tendinopathy | Insertional Achilles TendinopathyAustria
-
Brooke Army Medical CenterRecruitingLateral Elbow TendinopathyUnited States
-
Guna S.p.aRecruitingTendinopathy | Achilles Tendinopathy | Insertional Achilles Tendinopathy | PeritendinitisItaly
-
Elif Balevi BaturCompleted
-
Anika Therapeutics, Inc.Completed
-
University of DelawareRecruitingSever's Disease | Achilles Tendinopathy | Insertional Achilles Tendinopathy | Apophysitis; CalcaneusUnited States
-
Gelderse Vallei HospitalRecruiting
-
Maimonides UniversityRecruitingAchilles TendinopathyArgentina
Clinical Trials on Autologous Mesenchymal Stem Cells
-
Mayo ClinicNational Institute of Neurological Disorders and Stroke (NINDS); Food and Drug...Active, not recruiting
-
Mashhad University of Medical SciencesCompleted
-
University of JordanCompletedOsteoarthritis, Knee | Articular Cartilage Disorder of KneeJordan
-
Clínica Las Condes. LIT INNOVA CORFOUnknownSpinal Cord InjuryChile
-
Mayo ClinicCompletedAmyotrophic Lateral SclerosisUnited States
-
Karolinska InstitutetCompletedMultiple Sclerosis | Autologous Mesenchymal Stem CellsSweden
-
University of JordanCompletedMultiple SclerosisJordan
-
Antonio UccelliAzienda Ospedaliera Universitaria Integrata Verona; Ospedale San RaffaeleUnknown
-
Karolinska InstitutetCompleted
-
University of JordanCompletedSpinal Cord InjuriesJordan